Neurocrine Biosciences (NBIX) Share-based Compensation (2010 - 2026)
Neurocrine Biosciences (NBIX) posted quarterly Share-based Compensation of $65.0 million for Q2 2026, up 23.11% year-over-year from $52.8 million in Q2 2025, and up 13.64% on a QoQ basis from $57.2 million in Q1 2026.
Neurocrine Biosciences (NBIX) Share-based Compensation (2010 - 2026) Analysis & Trends
Neurocrine Biosciences has reported Share-based Compensation for 17 years, with the latest figure at $65.0 million in Q2 2026.
- Share-based Compensation for Q2 2026 came in at $65.0 million, up 23.11% year-over-year; the trailing twelve-month figure through Jun 2026 was $234.5 million (down 19.03% YoY), and the FY2025 annual result was $217.9 million, down 19.77% from the prior year.
- Share-based Compensation rose to $65.0 million in Q2 2026, from $57.2 million in the prior quarter.
- Over five years, Share-based Compensation peaked at $142.5 million in Q4 2024 and troughed at $37.0 million in Q1 2022.
- A 5-year average of $54.8 million and a median of $48.6 million in 2022 frame the typical range for Share-based Compensation.
- The widest annual swing landed in 2024, when Share-based Compensation soared 219.51%; it then slumped 58.88% in 2025.
- A 5-year view of Share-based Compensation shows it stood at $43.5 million in 2022, then advanced by 2.53% to $44.6 million in 2023, then soared by 219.51% to $142.5 million in 2024, then slumped by 58.88% to $58.6 million in 2025, then gained by 10.92% to $65.0 million in 2026.
- Per Business Quant data, the three most recent Share-based Compensation figures were $65.0 million in Q2 2026, $57.2 million in Q1 2026, and $58.6 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.28 Bn | 39.62 Bn | 2.15 Bn | 40.00 Mn |
| 3 | Zoetis | 31.79 Bn | 30.11 Bn | 1.05 Bn | 26.00 Mn |
| 4 | Takeda Pharmaceutical | 28.69 Bn | 22.89 Bn | 5.10 Bn | 114.12 Mn |
| 5 | United Therapeutics | 22.25 Bn | 19.58 Bn | 683.80 Mn | 19.00 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | 30.40 Mn |
| 7 | Neurocrine Biosciences | 15.58 Bn | 15.19 Bn | 935.80 Mn | 65.00 Mn |
| 8 | Elanco Animal Health | 11.87 Bn | 11.34 Bn | 798.00 Mn | 7.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | - |
| 10 | Alkermes | 8.15 Bn | 7.49 Bn | 397.90 Mn | 31.14 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 65.00 Mn |
| Jun 30, 2026 | 65.00 Mn |
| Mar 31, 2026 | 55.70 Mn |
| Mar 31, 2026 | 55.70 Mn |
| Sep 30, 2025 | -105.60 Mn |
| Sep 30, 2025 | -105.60 Mn |
| Jun 30, 2025 | 52.80 Mn |
| Jun 30, 2025 | 52.80 Mn |
| Mar 31, 2025 | 52.80 Mn |
| Mar 31, 2025 | 52.80 Mn |
| Dec 31, 2024 | 66.40 Mn |
| Dec 31, 2024 | 66.40 Mn |
| Sep 30, 2024 | 120.10 Mn |
| Sep 30, 2024 | 120.10 Mn |
| Jun 30, 2024 | -35.50 Mn |
| Jun 30, 2024 | -35.50 Mn |
| Mar 31, 2024 | 44.50 Mn |
| Mar 31, 2024 | 44.50 Mn |
| Dec 31, 2023 | 44.60 Mn |
| Dec 31, 2023 | 44.60 Mn |